KRAS and colonic neoplasm: Among studies assessing colon cancer cell lines, Ragusa et al. (16) found that exosomes derived from Caco-2 (KRAS wildtype) cells pretreated with cetuximab promote the viability of HCT-116 (KRAS mutant) cells.